Target protein degradation: Harnessing CRBN to discover potential breakthrough therapeutics

4:30 pm - Wednesday 27th January 2027

  • Elucidating thalidomide’s MoA led to realizing the promise of harnessing CRBN for targeted protein degradation
  • Structural insight into cereblon ternary complexes is guiding the optimization of targeted protein degraders
  • This platform is enabling the selective degradation of pathways implicated in multiple diseases

Speakers:

Scientific Director
Bristol Myers Squibb